Last reviewed · How we verify

Acute ST segment elevation myocardial infarction — Treatment Landscape & Competitive Intelligence

Acute ST segment elevation myocardial infarction (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Acute ST segment elevation myocardial infarction, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Plavix clopidogrel Generic (originally Sanofi/BMS) Thienopyridine antiplatelet agent Cytochrome P450 2B6, P2Y purinoceptor 12, Sodium-dependent serotonin transporter 1997-11-17

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Generic (originally Sanofi/BMS) · 1 drug in Acute ST segment elevation myocardial infarction

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Acute ST segment elevation myocardial infarction:

Cite this brief

Drug Landscape (2026). Acute ST segment elevation myocardial infarction — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/acute-st-segment-elevation-myocardial-infarction. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing